Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AstraZeneca's Hudson Optimistic On Return To Growth In 2017

Executive Summary

US President Paul Hudson talked in an interview at the J.P. Morgan Healthcare conference about the company’s budding oncology portfolio, upcoming launches and growing optimism as the 2017 return-to-growth goal approaches.

Advertisement

Related Content

AstraZeneca Diabetes Combo Needs More Clinical Data, FDA Says
AstraZeneca’s Iressa, Now Resurrected, Faces Daunting U.S. EGFR Market
With Anoro, GSK Takes A Two-Step Toward Bolstering Respiratory
AZ Doubles Down On Diabetes, Buys Out Bristol’s Share in Alliance
AZ Centers Pearl As The Jewel Of Its Respiratory Franchise
Is Brilinta The Treatment To Keep AstraZeneca’s Lifeblood Flowing?
AstraZeneca’s Ardea Acquisition: A Rich Deal Spurred By Phase III Gout Candidate

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

PS057402

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel